Insulet Corporation develops, manufactures, and sells insulin delivery systems for individuals with insulin-dependent diabetes. Its primary product is the Omnipod System, which includes a tubeless insulin delivery device and a wireless personal diabetes manager. Revenue primarily comes from sales of the Omnipod System, accounting for approximately 80-90% of total revenue, with the remainder generated from related accessories and services. Factors supporting endurance include the growing prevalence of diabetes and the increasing demand for innovative diabetes management solutions. However, competition from other insulin delivery systems and potential regulatory challenges could limit growth.
—
Insulet Corporation develops, manufactures, and sells insulin delivery systems for individuals with insulin-dependent diabetes. Its primary product is the Omnipod System, which includes a tubeless insulin delivery device and a wireless personal diabetes manager. Revenue primarily comes from sales of the Omnipod System, accounting for approximately 80-90% of total revenue, with the remainder generated from related accessories and services. Factors supporting endurance include the growing prevalence of diabetes and the increasing demand for innovative diabetes management solutions. However, competition from other insulin delivery systems and potential regulatory challenges could limit growth.
—
Daily adjusted close
Insulet Corporation develops, manufactures, and sells insulin delivery systems for individuals with insulin-dependent diabetes. Its primary product is the Omnipod System, which includes a tubeless insulin delivery device and a wireless personal diabetes manager. Revenue primarily comes from sales of the Omnipod System, accounting for approximately 80-90% of total revenue, with the remainder generated from related accessories and services. Factors supporting endurance include the growing prevalence of diabetes and the increasing demand for innovative diabetes management solutions. However, competition from other insulin delivery systems and potential regulatory challenges could limit growth.